Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navicixizumab + FOLFIRI/FOLFOX in mCRC
NCT03035253Phase 1Terminated
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navicixizumab in metastatic colorectal cancer (mCRC), sponsored by OncoMed Pharmaceuticals. Primary endpoint: Incidence of dose limiting toxicities at 28 days. Started Dec 2016; status: terminated.
02
Drugs
navicixizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03035253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035253.